Matrix Biology | VOL. 111
Read

Aberrant TIMP-1 overexpression in tumor-associated fibroblasts drives tumor progression through CD63 in lung adenocarcinoma

Publication Date Aug 1, 2022

Abstract

Tissue inhibitor of metalloproteinase-1 (TIMP-1) is an important regulator of extracellular matrix turnover that has been traditionally regarded as a potential tumor suppressor owing to its inhibitory effects of matrix metalloproteinases. Intriguingly, this interpretation has been challenged by the consistent observation that increased expression of TIMP-1 is associated with poor prognosis in virtually all cancer types including lung cancer, supporting a tumor-promoting function. However, how TIMP-1 is dysregulated within the tumor microenvironment and how it drives tumor progression in lung cancer is poorly understood. We analyzed the expression of TIMP-1 and its cell surface receptor CD63 in two major lung cancer subtypes: lung adenocarcinoma (ADC) and squamous cell carcinoma (SCC), and defined the tumor-promoting effects of their interaction. We found that TIMP-1 is aberrantly overexpressed in tumor-associated fibroblasts (TAFs) in ADC compared to SCC. Mechanistically, TIMP-1 overexpression was mediated by the selective hyperactivity of the pro-fibrotic TGF-β1/SMAD3 pathway in ADC-TAFs. Likewise, CD63 was upregulated in ADC compared to SCC cells. Genetic analyses revealed that TIMP-1 secreted by TGF-β1-activated ADC-TAFs is both necessary and sufficient to enhance growth and invasion of ADC cancer cells in culture, and that tumor cell expression of CD63 was required for these effects. Consistently, in vivo analyses revealed that ADC cells co-injected with fibroblasts with reduced SMAD3 or TIMP-1 expression into immunocomp...

Concepts

Tissue Inhibitor Of Metalloproteinase-1 Aberrant Overexpression Tissue Inhibitor Of Metalloproteinase-1 Overexpression Tumor Progression In Lung Cancer Major Lung Cancer Subtypes Therapeutic Target In Lung Cancer Expression Of Tissue Inhibitor Of Metalloproteinase-1 Lung Adenocarcinoma Progression In Lung Cancer Cancer Cells In Culture

Round-ups are the summaries of handpicked papers around trending topics published every week. These would enable you to scan through a collection of papers and decide if the paper is relevant to you before actually investing time into reading it.

Coronavirus Research Articles published between Sep 26, 2022 to Oct 02, 2022

R DiscoveryOct 03, 2022
R DiscoveryArticles Included:  5

Introduction: Test solutions (Biotrue, renu Advanced [Bausch and Lomb], ACUVUE RevitaLens [Johnson and Johnson Vision], cleadew [Ophtecs corp.] or AOS...

Read More

Good health Research Articles published between Sep 26, 2022 to Oct 02, 2022

R DiscoveryOct 03, 2022
R DiscoveryArticles Included:  2

Patient and public involvement in health care is considered indispensable in the way we conduct daily pediatric neurology practice, and in the develop...

Read More

Quality Of Education Research Articles published between Sep 26, 2022 to Oct 02, 2022

R DiscoveryOct 03, 2022
R DiscoveryArticles Included:  5

Ingenta is not the publisher of the publication content on this website. The responsibility for the publication content rests with the publishers prov...

Read More

Gender Equality Research Articles published between Sep 26, 2022 to Oct 02, 2022

R DiscoveryOct 03, 2022
R DiscoveryArticles Included:  3

Introduction: As of early March 2022, the COVID-19 pandemic has killed more 5.9 million people worldwide, and infected more than 437 million.

Read More

Coronavirus Pandemic

You can also read COVID related content on R COVID-19

R ProductsCOVID-19

ONE PROBLEM . ONE PURPOSE . ONE PLACE

Creating the world’s largest AI-driven & human-curated collection of research, news, expert recommendations and educational resources on COVID-19

COVID-19 Dashboard

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on “as is” basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The Copyright Law.